Applications Henri Termeer Transatlantic Connections Award Open!
Are you the next emerging biotech entrepreneur of the Netherlands or Massachusetts? Do you want to have access to experienced biotech mentors and network with fellow peer entrepreneurs within the Henri Termeer Foundation community? Then apply now for the third edition of the prestigious Henri Termeer Transatlantic Connections Award. Apply here.
The Henri Termeer Transatlantic Connections Award is established by The Termeer Foundation, in partnership with Health~Holland, to honor and recognize two emerging biotech entrepreneurs; one in Massachusetts and one in the Netherlands. Awardees become members of the 2023 Class of Termeer Fellows and join the Termeer network, an ever-expanding network of biotech entrepreneurs, CEOs and visionaries and recognition at the annual Termeer Fellows Celebration.
Awardees lead innovative biomedical research activities and their programs have the potential to strengthen the transatlantic relation between the two life sciences regions. Candidates will be selected based upon their entrepreneurial success in establishing a life science company that meets certain criteria like leadership capabilities, scientific and financial track record. Next to that, they exhibit a strong interest in mentoring other young entrepreneurs and a willingness for additional involvement in the Termeer Foundation Programs.
Applications for the 2023 Henri Termeer Transatlantic Connections Award are currently open until Friday January 6 2023. Please find the nomination from here.
The 2022 Henri Termeer Transatlantic Connections Award honorees were: Kasper Roet, CEO and co-founder of, QurAlis Corporation; and Koenraad Wiedhaup, CEO and founder of Leyden Labs.
~ Kasper Roet, PhD, is CEO and co-founder of QurAlis Corporation. He is also co-founder and serves on the board of directors of EnClear Therapies. Kasper is a passionate neuroscientist and therapy developer who specializes in gene therapies and stem cell technology-based precision medicine solutions for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Kasper’s work at the Netherlands Brain Bank emphasized the need for effective treatments for patients and their families. Upon seeing the incredible achievements in stem cell modeling and gene discoveries in ALS, Kasper realized that this is the time to make a real difference for patients.
He decided to move to Boston from the Netherlands with his wife, and work with two visionary leaders in ALS stem cell disease modeling, Harvard professors Clifford Woolf and Kevin Eggan with whom he co-founded QurAlis to bring breakthrough precision therapies for ALS and other neurodegenerative diseases. Kasper was trained by industry thought leaders at Johnson and Johnson along with forward-thinking scientific and business thought leaders at Harvard University. Kasper obtained his PhD degree at the Netherlands Institute for Neuroscience and the Free University of Amsterdam and obtained a master’s degree with honors from the University of Amsterdam. Kasper was awarded the Milton Safenowitz postdoctoral fellowship from the ALS Association. With QurAlis, Kasper won two Golden Tickets (Amgen 2017 and Pfizer 2018), became a JLabs member in 2018, and won the Fierce15 Biotech award in 2020.
~ Koenraad Wiedhaup is a founder and the CEO of Leyden Labs, a biotech company that aims to free people from the threat of viruses by developing mucosal products. He is committed to helping people strive for a fantastic life by bringing scientific developments to those who need them.
Before his current role, he was a Partner with McKinsey & Company’s Life Science practice where he advised pharmaceutical, biotech and medtech companies throughout Europe and the US.
Koenraad has a background in Science, studying Life Sciences and Biotechnology at the Universities of Leiden and Delft and in Business, with an MBA from Columbia Business School in New York. Koenraad started his career at a biotech company in the San Francisco Bay Area.
Source: The Termeer Foundation
